Study designs of evaluations included in the review
Controlled trials that reported sudden cardiac death as a separate end point were included.
Specific interventions included in the review
NPSDs (bendroflumethiazide, chlorthalidone, chlorothiazide, hydrochlorothiazide, methychlothiazide).
Participants included in the review
Males and females with mild-to-moderate hypertension.
Outcomes assessed in the review
Sudden cardiac death. Serum potassium and magnesium levels, and cardiac arrhythmias were also assessed as intermediate outcomes, but are not discussed in this abstract.
How were decisions on the relevance of primary studies made?
The authors do not state how the papers were selected for the review, or how many of the authors performed the selection.